» Articles » PMID: 34131208

Adipogenesis in Triple-negative Breast Cancer is Associated with Unfavorable Tumor Immune Microenvironment and with Worse Survival

Overview
Journal Sci Rep
Specialty Science
Date 2021 Jun 16
PMID 34131208
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer-associated adipocytes are known to cause inflammation; however, the role of adipogenesis, the formation of adipocytes, in breast cancer is unclear. We hypothesized that intra-tumoral adipogenesis reflects a different cancer biology than abundance of intra-tumoral adipocytes. The Molecular Signatures Database Hallmark adipogenesis gene set of gene set variant analysis was used to quantify adipogenesis. Total of 5,098 breast cancer patients in multiple cohorts (training; GSE96058 (n = 3273), validation; TCGA (n = 1069), treatment response; GSE25066 (n = 508) and GSE20194 (n = 248)) were analyzed. Adipogenesis did not correlate with abundance of adipocytes. Adipogenesis was significantly lower in triple negative breast cancer (TNBC). Elevated adipogenesis was significantly associated with worse survival in TNBC, but not in the other subtypes. High adipogenesis TNBC was significantly associated with low homologous recombination deficiency, but not with mutation load. High adipogenesis TNBC enriched metabolism-related gene sets, but neither of cell proliferation- nor inflammation-related gene sets, which were enriched to adipocytes. High adipogenesis TNBC was infiltrated with low CD8 T cells and high M2 macrophages. Although adipogenesis was not associated with neoadjuvant chemotherapy response, high adipogenesis TNBC was significantly associated with low expression of PD-L1 and PD-L2 genes, and immune checkpoint molecules index. In conclusion, adipogenesis in TNBC was associated with cancer metabolism and unfavorable tumor immune microenvironment, which is different from abundance of adipocytes.

Citing Articles

Bisphenol A and DDT disrupt adipocyte function in the mammary gland: implications for breast cancer risk and progression.

Bernhardt S, House C Front Oncol. 2025; 15:1490898.

PMID: 40034592 PMC: 11873108. DOI: 10.3389/fonc.2025.1490898.


Dissecting tumor cell programs through group biology estimation in clinical single-cell transcriptomics.

Johri S, Bi K, Titchen B, Fu J, Conway J, Crowdis J Nat Commun. 2025; 16(1):2090.

PMID: 40025015 PMC: 11873288. DOI: 10.1038/s41467-025-57377-6.


Adipogenesis biomarkers as the independent predictive factors for breast cancer recurrence: a systematic review and meta-analysis.

Hu S, Tey S, Kwong A BMC Cancer. 2024; 24(1):1181.

PMID: 39333940 PMC: 11438415. DOI: 10.1186/s12885-024-12931-1.


Obesity-Associated Breast Cancer: Analysis of Risk Factors and Current Clinical Evaluation.

Engin A Adv Exp Med Biol. 2024; 1460:767-819.

PMID: 39287872 DOI: 10.1007/978-3-031-63657-8_26.


Next-Cell Hypothesis: Mechanism of Obesity-Associated Carcinogenesis.

Engin A, Engin A Adv Exp Med Biol. 2024; 1460:727-766.

PMID: 39287871 DOI: 10.1007/978-3-031-63657-8_25.


References
1.
Telli M, Stover D, Loi S, Aparicio S, Carey L, Domchek S . Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer. Breast Cancer Res Treat. 2018; 171(1):21-31. DOI: 10.1007/s10549-018-4807-x. View

2.
Oshi M, Newman S, Murthy V, Tokumaru Y, Yan L, Matsuyama R . ITPKC as a Prognostic and Predictive Biomarker of Neoadjuvant Chemotherapy for Triple Negative Breast Cancer. Cancers (Basel). 2020; 12(10). PMC: 7601042. DOI: 10.3390/cancers12102758. View

3.
Iyengar N, Gucalp A, Dannenberg A, Hudis C . Obesity and Cancer Mechanisms: Tumor Microenvironment and Inflammation. J Clin Oncol. 2016; 34(35):4270-4276. PMC: 5562428. DOI: 10.1200/JCO.2016.67.4283. View

4.
Balli D, Rech A, Stanger B, Vonderheide R . Immune Cytolytic Activity Stratifies Molecular Subsets of Human Pancreatic Cancer. Clin Cancer Res. 2016; 23(12):3129-3138. DOI: 10.1158/1078-0432.CCR-16-2128. View

5.
Oshi M, Takahashi H, Tokumaru Y, Yan L, Rashid O, Matsuyama R . G2M Cell Cycle Pathway Score as a Prognostic Biomarker of Metastasis in Estrogen Receptor (ER)-Positive Breast Cancer. Int J Mol Sci. 2020; 21(8). PMC: 7215898. DOI: 10.3390/ijms21082921. View